Molecular insights into the anti-cancer properties of Traditional Tibetan medicine Yukyung Karne

BMC Complementary and Alternative Medicine

Vijay Kumar²  Ganeshan Mathan³  Dawa Dolma¹  Tenzin Choedon³ 

[1] Tibetan Medical Astro Institute, Dharamsala, Kangra 176215, India;Virology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067, India;Department of Biomedical Science, Bharathidasan University, Tiruchirappalli 620024, India

关键词: Mitochondria membrane potential;    Apoptosis;    Ovarian cancer;    Traditional Tibetan medicine;    Yukyung Karne;   

Others  :  1086321
DOI  :  10.1186/1472-6882-14-380

 received in 2014-03-17, accepted in 2014-10-03,  发布年份 2014

【 摘 要 】

Background

Yukyung karne (YK) is a traditional Tibetan formulation used for many centuries for the treatment of ovarian cancer. However, the pharmacological basis of its anticancer property is not well understood. In the present study, the anticancer property of YK was investigated in cell culture.

Methods

The growth inhibitory property of YK was evaluated in SKOV6, IHH, HepG2 and HEK293 cell lines using MTT assay. The pro-apoptotic activity of drug was analyzed by terminal deoxynuleotidyl transferase dUTP nick end labeling (TUNEL) and DNA fragmentation assays. Confocal microscopy was used to show the release of cytochrome c and its co-localization with mitochondria with the help of dsRed mitotracker in SKOV6 cells. The inhibition in cell proliferation was also visualized by confocal microscopy after BrDU incorporation. The activation of tumor suppressor p53 was evaluated by Western blotting while VEGF levels in culture supernatant were measured by a colorimetric method.

Results

YK specifically and efficiently induced apoptotic killing of the human ovarian cancer SKOV6 cells as indicated by increased DNA fragmentation and nick end DNA labeling. Confocal microscopy suggested inhibition of cell proliferation and increase in cytochrome c release via perturbation in mitochondrial membrane potential (Δψm). Further, YK up-regulated the expression of tumor suppressor p53 and key cyclin-dependent kinase inhibitor p21, and inhibited VEGF secretion by cells. Interestingly, YK also exhibited a synergy with paclitaxel which is a well-known anti-cancer therapeutic drug.

Conclusions

The pharmacological properties of YK to impose growth arrest and trigger pro-apoptotic death in cells amply justify its usage in primary as well as adjunct therapy for ovarian cancer.

【 授权许可】

   
2014 Choedon et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M: MDR gene expression analysis of six drug resistant ovarian cancer cell lines. Biomed Res Int 2013, 2013:241763.
• [2]Kim A, Ueda Y, Naka T: Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 2012, 31:14. BioMed Central Full Text
• [3]Dobbin ZC, Landen CN: The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 2013, 14:8213-8227.
• [4]Song MK, Roufogalis BD, Huang THW: Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology. Br J Pharmacol 2012, 165:4-19.
• [5]Lin YG, Kunnumakkara AB, Nair A, Meritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the Nuclear Factor-kB pathway. Clin Cancer Res 2007, 13:3423-3430.
• [6]Cheung CW, Gibbons N, Johnson DW, Nicol DL: Silibinin—a promising new treatment for cancer. Anticancer Agents Med Chem 2010, 10:186-195.
• [7]Choedon T, Kumar V: Medicinal plants used in the practice of Tibetan medicine. In Recent progress in Medicinal plants, Volume 34. USA: Stadium Press LLC; 2012:385-402. [Phytoconstituents and Physiological processes]
• [8]Sandhya T, Lathika KM, Pandey BN, Mishra KP: Potential of traditional ayurvedic formulation, Triphala, as a novel anticancer drug. Cancer Lett 2006, 231:206-214.
• [9]Keith CT, Borisy AA, Stockwell BR: Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005, 4:71-78.
• [10]Randal J: Diagnosis, Tibetan style, underlies small herbal study of advanced breast cancer. J Natl Cancer Inst 1999, 91:587-588.
• [11]Sallon S, Namdul T, Dolma S, Dorjee P, Dolma D, Sadutshang T, Ever-Hadani P, Bdolah-Abram T, Apter S, Almog S, Roberts S: Mercury in traditional Tibetan medicine- panacea or problem? Hum Exp Toxicol 2006, 25:405-412.
• [12]Ginsburg I, Koren E, Horani A, Mahamid M, Doron S, Muhanna N, Amer J, Safadi R: Amelioration of hepatic fibrosis via Padma Hepaten is associated with altered natural killer T lymphocytes. Clin Exp Immunol 2009, 157:155-164.
• [13]Choedon T, Dolma D, Kumar V: Proapoptotic and anticancer properties of Thapring- a Tibetan herbal formulation. J Ethnopharmacol 2011, 137:320-326.
• [14]Dawa: Bod kyi Gso Ba Rigpa Las Sman Rdzas Sbyor lag len Gsan Sgo byed Pai Lde Mig. Dharamsala, India: RigDrag publication; 2003.
• [15]Van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM: A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 1994, 174:311-320.
• [16]Peng B, Chang Q, Wang L, Hu Q, Wang Y, Tang J, Liu X: Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis. Gynecol Oncol 2008, 108:173-181.
• [17]Mukherji A, Janbandhu VC, Kumar V: HBx –dependent cell cycle deregulation involves interaction with cyclin E/A-cdk2 complex and destabilization of p27Kip1. Biochem J 2007, 401:247-256.
• [18]Menendez D, Inga A, Resnick MA: Potentiating the p53 network. Discov Med 2010, 10:94-100.
• [19]Giannattasio S, Guaragnella N, Arbini AA, Moro L: Stress-related mitochondrial components and mitochondrial genome as targets of anticancer therapy. Chem Biol Drug Des 2013, 81:102-112.
• [20]Greenberg JI, Cheresh DA: VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 2009, 9:1347-1356.
• [21]Nakayama KI, Nakayama K: Ubiquitin ligases: cell cycle control and cancer. Nat Rev Cancer 2006, 6:369-380.
• [22]Darwiche N, El-Banna S, Gali-Muhtasib H: Cell cycle modulatory and apoptotic effect of plant–derived anticancer drugs in clinical use or development. Expert Opin Drug Discov 2007, 2:361-379.
• [23]Longley DB, Johnston PG: Molecular mechanism of drug resistance. J Pathol 2005, 205:275-292.
• [24]Mouratidou D, Gennatas C, Michalaki V, Papadimitriou A, Andreadis CH, Sykiotis C, Tsavaris N: A Phase III Randomized study comparing Paclitaxel and Cisplatin versus Cyclophosphamide and Cisplatin in patients with advanced ovarian cancer. Anticancer Res 2007, 27:681-686.
• [25]Martinou JC, Desagher S, Antonsson B: Cytochrome c release from mitochondria: all or nothing. Nat Cell Biol 2000, 2:E41-E43.
• [26]Malumbres M, Carnero A: Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res 2003, 5:5-18.
• [27]Ehrhardt H, Wachter F, Grunert M, Jeremias I: Cell cycle –arrested tumor cells exhibit increased sensitivity towards TRAIL- induced apoptosis. Cell Death Dis 2013, 4:e661.
• [28]Fulda S, Debatin KM: Sensitization for anticancer drug- induced apoptosis by betulinic acid. Neoplasia 2005, 7:162-170.
• [29]Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
• [30]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.